Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

Impact · against what's priced in

Nurix Therapeutics receives a major valuation catalyst through a high-value collaboration with Roche, securing $700 million upfront and expanding the clinical scope of bexobrutideg into immunology and neurology. For Roche, the deal strategically strengthens its B-cell portfolio with a potential best-in-class BTK degrader.

NRIX+1.00: No priced-in read yet

Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

What matters in this story

Ardelyx Deadline: ARDX Investors with Losses in Excess of $100K Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit

Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

What matters in this story

Ardelyx Deadline: ARDX Investors with Losses in Excess of $100K Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit

How each ticker is affected

Connected tickers

Track these names every morning.

Regeneron: 3 Key Takeaways for Long-Term Investors

AbbVie: 3 Key Takeaways for Long-Term Investors

Is AbbVie a Buy After Its Latest Earnings Report?

TENX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Tenax Therapeutics (TENX) Investors of Securities Class Action Lawsuit Deadline on December 28, 2026

Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

What matters in this story

Next reads from the same story arc

Ardelyx Deadline: ARDX Investors with Losses in Excess of $100K Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit

Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

What matters in this story

Next reads from the same story arc

Ardelyx Deadline: ARDX Investors with Losses in Excess of $100K Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit

How each ticker is affected

Connected tickers

Track these names every morning.

Regeneron: 3 Key Takeaways for Long-Term Investors

AbbVie: 3 Key Takeaways for Long-Term Investors

Is AbbVie a Buy After Its Latest Earnings Report?

TENX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Tenax Therapeutics (TENX) Investors of Securities Class Action Lawsuit Deadline on December 28, 2026